MIRM Stock Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Mirum Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$19.98|
|52 Week High||US$28.65|
|52 Week Low||US$12.82|
|1 Month Change||-20.81%|
|3 Month Change||-16.99%|
|1 Year Change||19.28%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||51.25%|
Recent News & Updates
Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
Mirum's maralixibat was approved in September. The company looks like it is executing very well. I am waiting for dips to buy back in.
|MIRM||US Biotechs||US Market|
Return vs Industry: MIRM exceeded the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: MIRM exceeded the US Market which returned -21.2% over the past year.
|MIRM Average Weekly Movement||9.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MIRM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MIRM's weekly volatility (10%) has been stable over the past year.
About the Company
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.
Mirum Pharmaceuticals Fundamentals Summary
|MIRM fundamental statistics|
Is MIRM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MIRM income statement (TTM)|
|Cost of Revenue||US$4.33m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.20|
|Net Profit Margin||-218.74%|
How did MIRM perform over the long term?See historical performance and comparison
Is MIRM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MIRM?
Other financial metrics that can be useful for relative valuation.
|What is MIRM's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MIRM's PS Ratio compare to its peers?
|MIRM PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
VNDA Vanda Pharmaceuticals
SGMO Sangamo Therapeutics
ORGO Organogenesis Holdings
MIRM Mirum Pharmaceuticals
Price-To-Sales vs Peers: MIRM is good value based on its Price-To-Sales Ratio (19.9x) compared to the peer average (116.7x).
Price to Earnings Ratio vs Industry
How does MIRM's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: MIRM is expensive based on its Price-To-Sales Ratio (19.9x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is MIRM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||19.9x|
|Fair PS Ratio||13.8x|
Price-To-Sales vs Fair Ratio: MIRM is expensive based on its Price-To-Sales Ratio (19.9x) compared to the estimated Fair Price-To-Sales Ratio (13.8x).
Share Price vs Fair Value
What is the Fair Price of MIRM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MIRM ($19.98) is trading below our estimate of fair value ($264.8)
Significantly Below Fair Value: MIRM is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MIRM's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Mirum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MIRM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: MIRM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MIRM is expected to become profitable in the next 3 years.
Revenue vs Market: MIRM's revenue (48.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: MIRM's revenue (48.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MIRM is forecast to be unprofitable in 3 years.
Discover growth companies
How has Mirum Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MIRM is currently unprofitable.
Growing Profit Margin: MIRM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MIRM is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare MIRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIRM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: MIRM has a negative Return on Equity (-64.32%), as it is currently unprofitable.
Discover strong past performing companies
How is Mirum Pharmaceuticals's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MIRM's short term assets ($155.3M) exceed its short term liabilities ($34.6M).
Long Term Liabilities: MIRM's short term assets ($155.3M) exceed its long term liabilities ($134.7M).
Debt to Equity History and Analysis
Debt Level: MIRM is debt free.
Reducing Debt: MIRM has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MIRM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MIRM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Mirum Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MIRM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MIRM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Peetz (43 yo)
Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He joined Frazier on May 30, 2017. He is on the Frazier Life Sciences team (...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD4.13M) is about average for companies of similar size in the US market ($USD4.03M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
Experienced Management: MIRM's management team is considered experienced (2.8 years average tenure).
Experienced Board: MIRM's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.
Mirum Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Mirum Pharmaceuticals, Inc.
- Ticker: MIRM
- Exchange: NasdaqGM
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$636.194m
- Shares outstanding: 31.84m
- Website: https://www.mirumpharma.com
Number of Employees
- Mirum Pharmaceuticals, Inc.
- 950 Tower Lane
- Suite 1050
- Foster City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.